To view this email as a web page, click here.

Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for Prostate Cancer

A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for metastatic castration-resistant prostate cancer.

Benefits With Gilteritinib for AML Were Maintained, Regardless of Co-Mutations

The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.

IN CASE YOU MISSED IT

Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.